Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Operating Expenses (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Other Operating Expenses over the past 3 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $1.1 million for Q4 2025, down 10.57% from a year ago — trailing twelve months through Dec 2025 was $6.6 million (down 90.05% YoY), and the annual figure for FY2025 was $6.6 million, down 90.05%.
  • Other Operating Expenses for Q4 2025 was $1.1 million at Tonix Pharmaceuticals Holding, down from $1.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for TNXP hit a ceiling of $62.3 million in Q2 2024 and a floor of -$29.7 million in Q2 2023.
  • Median Other Operating Expenses over the past 3 years was $1.2 million (2024), compared with a mean of -$1.1 million.
  • Biggest five-year swings in Other Operating Expenses: soared 309.63% in 2024 and later plummeted 94.75% in 2025.
  • Tonix Pharmaceuticals Holding's Other Operating Expenses stood at -$28.7 million in 2023, then skyrocketed by 104.13% to $1.2 million in 2024, then decreased by 10.57% to $1.1 million in 2025.
  • The last three reported values for Other Operating Expenses were $1.1 million (Q4 2025), $1.4 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.